USA flag logo/image

An Official Website of the United States Government

Commercializing digital wireless telemetry: the animal epilepsy monitoring unit

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
76436
Program Year/Program:
2008 / STTR
Agency Tracking Number:
NR009877
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIO-SIGNAL GROUP CORPORATION
SUNY DOWNSTATE MEDICAL CENTER BOX 1247 NEW YORK, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2008
Title: Commercializing digital wireless telemetry: the animal epilepsy monitoring unit
Agency: HHS
Contract: 9R42NS064474-02A1
Award Amount: $665,895.00
 

Abstract:

DESCRIPTION (provided by applicant): Bio-Signal Group Corp. developed a miniature, battery-operated, multi-channel, portable digital telemetry system to record wideband bioelectric signals. DT measures biopotentials with high precision because it digitiz es signals on the subject at 24-bit resolution. Perhaps the most obvious feature that distinguishes the DT from other telemetric systems is the DT is designed to record both fast and slow brain potentials such as action potentials (AP; 0.3-6kHz) and local field potential (LFP) oscillations that range from 0.1 to 500 Hz. Wireless data transmission with DT is robust up to 10 m in virtually any environment. A pair of 2.4 GHz transceivers guarantees a data rate of 1.536 Mb/s. The communication system of DT has no constraints on the origin of the digital data it transmits. The data comprising the 1.536 Mb/s can be arranged in any way by the microprocessor (MCU). DT has advantages over analog solutions for assessing signal fidelity, providing error correction and avoiding signal distortion during transmission (very difficult with analog transmission). A key advantage over competing analog systems is digital signal processing can occur at the signal source before the data are transmitted from the subject. The innova tion means data can be optimized, compressed, and transmitted free of distortion. In Phase I, BSG demonstrated the feasibility of using DT to make electrophysiological recordings from freely-moving rats in the laboratory. We exhibited 2,4 and 8-ch prototyp e devices and meticulously gathered feedback from 296 neuroscientists who visited the exhibit at the last three Society for Neuroscience (SfN) meetings. This feedback helped identify a specific need for DT to record spontaneous seizures in laboratory anima ls. The specific technical developments required to create a commercial turn-key animal epilepsy monitoring unit (aEMU) are being proposed for this Phase II project. In Phase II we will: 1) miniaturize the transmitter stage; 2) optimize the transmitter sta ge for dense and parallel recordings; 3) synchronize the electrophysiological data with digital video recording; and 4) create software for analysis of the large database that will emerge from use of the aEMU. PUBLIC HEALTH RELEVANCE: Understanding epileps y amounts to understanding the detailed relationship between the electrical activity of the brain and the spontaneous occurrence of seizures. This project will create an animal epilepsy monitoring unit (aEMU) to allow researchers to record spontaneous brai n activity in laboratory animals that have spontaneous seizures. The aEMU will permit indefinitely long recordings in the animal's home environment, and software will also be created for analyzing the large database of information to help reveal key physio logical mechanisms that may predict seizure events and ultimately lead to their control in clinical treatments.

Principal Investigator:

Business Contact:


jgridley@biosignalgroup.com
Small Business Information at Submission:

BIO-SIGNAL GROUP CORPORATION
SUNY DOWNSTATE MEDICAL CENTER BOX 1247 NEW YORK, NY 11203

EIN/Tax ID: 522377842
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No